C4 Therapeutics Valuation
| CCCC Stock | USD 2.19 0.05 2.34% |
Based on Macroaxis valuation methodology, the entity appears to be fairly valued. C4 Therapeutics owns a latest Real Value of $2.05 per share. The recent price of the entity is $2.19. Our model approximates the value of C4 Therapeutics from evaluating the entity fundamentals such as Shares Owned By Insiders of 11.51 %, return on asset of -0.2, and Shares Outstanding of 70.99 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting C4 Therapeutics' valuation include:
Price Book 0.6836 | Enterprise Value | Enterprise Value Ebitda (0.42) | Price Sales 4.2693 | Enterprise Value Revenue 8.8457 |
Fairly Valued
Today
Please note that C4 Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of C4 Therapeutics is based on 3 months time horizon. Increasing C4 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since C4 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CCCC Stock. However, C4 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.19 | Real 2.05 | Target 16.38 | Hype 2.14 | Naive 2.18 |
The real value of CCCC Stock, also known as its intrinsic value, is the underlying worth of C4 Therapeutics Company, which is reflected in its stock price. It is based on C4 Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of C4 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of C4 Therapeutics helps investors to forecast how CCCC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of C4 Therapeutics more accurately as focusing exclusively on C4 Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use C4 Therapeutics' intrinsic value based on its ongoing forecasts of C4 Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against C4 Therapeutics' closest peers. If more than one evaluation category is relevant for C4 Therapeutics we suggest using both methods to arrive at a better estimate.
C4 Therapeutics Cash |
|
CCCC Valuation Trend
Comparing C4 Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of C4 Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
C4 Therapeutics Total Value Analysis
C4 Therapeutics is currently forecasted to have valuation of (31.49 M) with market capitalization of 151.92 M, debt of 133.62 M, and cash on hands of 307.78 M. The negative valuation of C4 Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the C4 Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(31.49 M) | 151.92 M | 133.62 M | 307.78 M |
C4 Therapeutics Investor Information
About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. C4 Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.56. The firm had not issued any dividends in recent years. Based on the key indicators related to C4 Therapeutics' liquidity, profitability, solvency, and operating efficiency, C4 Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.C4 Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. C4 Therapeutics has an asset utilization ratio of 10.18 percent. This indicates that the Company is making $0.1 for each dollar of assets. An increasing asset utilization means that C4 Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.C4 Therapeutics Ownership Allocation
C4 Therapeutics secures a total of 70.99 Million outstanding shares. The majority of C4 Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in C4 Therapeutics to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in C4 Therapeutics. Please pay attention to any change in the institutional holdings of C4 Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost two million one hundred fourty-three thousand eight hundred eighty-nine invesors are currently shorting C4 Therapeutics expressing very little confidence in its future performance.C4 Therapeutics Profitability Analysis
The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (75.05 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates C4 Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in C4 Therapeutics and how it compares across the competition.
About C4 Therapeutics Valuation
The stock valuation mechanism determines C4 Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of C4 Therapeutics. We calculate exposure to C4 Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of C4 Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -87.3 M | -82.9 M | |
| Pretax Profit Margin | (7.27) | (6.91) | |
| Operating Profit Margin | (7.70) | (7.32) | |
| Net Loss | (7.34) | (6.97) | |
| Gross Profit Margin | (5.37) | (5.10) |
C4 Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 70.6 M |
C4 Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of C4 Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CCCC we look at many different elements of the entity such as CCCC's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as C4 Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use C4 Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes C4 Therapeutics' worth.Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |